National Broadcast Television Program To Include Interview With Company’s Chairman
Dallas, TX and New York, NY, November 19, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that its Chairman, Steven Rouhandeh, will appear on WALLSTREETCAST, a national weekly television program airing on the FOX Business Network. The show will air tomorrow, Saturday, November 20th at 1:30 PM ET. The segment may also be viewed online at http://www.moneychannel.tv.
Read more »
Conference Hosted by the Cancer Prevention and Research Institute of Texas (CPRIT)
Dallas, TX and New York, NY, November 17, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that two oncology posters are being displayed this week at the Innovations in Cancer Prevention and Research Conference at the Austin Convention Center in Austin, TX. The poster being displayed, entitled “Vitamin B-12 Nanoparticles for the Targeted Delivery of RNAi Therapeutics”, summarizes key findings of the Company’s rebranded Cobalamin program, CobaCyte for RNAi. The second poster, entitled “Preclinical and Clinical Studies of ProLindac: A Novel Polymer Prodrug of DACH Platinum”, details the distinct attributes and advantages of utilizing Access’ second generation DACH Platinum, ProLindac.
Read more »
Dallas, TX and New York, NY, November 11, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that it will be presenting a poster today at the 10th Annual Diabetes Technology Meeting, entitled, “Preclinical Studies with Cobalamin™ Nanoparticles for Oral Drug Delivery of Insulin.” The poster reviews the progress made by Access scientists in developing its proprietary oral insulin formulation. Access recently rebranded its oral drug delivery technology as CobOralTM to reflect the advances made with the technology platform.
Read more »
Chairman To Provide Update To Investors On Company’s Recent Developments
Dallas, TX and New York, NY, November 09, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that its Chairman, Steven Rouhandeh, will present at the 1st Annual LifeTech Capital Miami Medical Investors Conference on Friday, November 12, 2010, at 1:00 pm ET. The conference is being held at the JW Marriot Marquis in Miami, Florida.
Read more »
Multicenter, Open-label Trial to Target Platinum-Sensitive Ovarian-Cancer Patients
Dallas, TX and New York, NY, November 3, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has commenced a Phase 2 combination trial for its second generation DACH-platinum cancer drug, ProLindac, in platinum-sensitive ovarian-cancer patients. This trial is an open-label, Phase 2 study of ProLindac given intravenously with paclitaxel. The combination trial will be conducted in up to eight European participating centers.
Read more »
Grants Cover ProLindac, Thiarabine, MuGard, CobOral Oral Insulin and CobaCyte siRNA Delivery Programs
Dallas, TX and New York, NY, November 1, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has been awarded $1.5 million in government grants. Under the recently enacted Patient Protection and Affordable Care Act, cash grants were awarded to Qualifying Therapeutic Discovery Projects that showed significant potential in producing new and cost-saving therapies, support job growth and increase U.S. competitiveness. Grants were awarded through a competitive application process, and seven out of eight Access Pharmaceutical applications were awarded.
Read more »
Digg!
Del.icio.us
NIH estimates that 90% of all radiation patients and 40% of chemotherapy patients experience oral mucositis! #MuGard #cancer